Syringomycin-family Lipodepsipeptides as Anti-Protozoan Agents

Researchers at Utah State University have developed a method to control or prevent protozoan infections caused by vector borne parasites through therapeutically effective amounts of a natural product and are seeking a party interested in licensing technology.

  • Wind farm prospecting
  • Aircraft/satellite applications
  • Measuring fluid flow
  • Cryptosporidiosis
  • Malaria
  • Leishmaniasis
  • Trypanosomiasis (Chagas disease)
  • Prevention of infection in immune compromised subjects
  • Alleviate protozoan drug resistance

  • Treats infections in immune compromised subjects, saving the lives of children, the elderly and the ill
  • Controls infections caused by protozoans, decreasing the spread of disease
  • Alleviates protozoan drug resistance, innovating the treatment of protozoan infections


US 6,310,037

Patent Information:
For Information, Contact:
Christian Iverson
Utah State University
Jon Takemoto